SWOG clinical trial number
CTSU/A031201

Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Closed
Phase
Abbreviated Title
Metastatic Prostate Ca, Enzalutamide vs. Enzalutamide, Abiraterone, and Prednisone, PhIII
Status Notes
This study permanently closed to accrual effective August 31, 2016 at 4:30 p.m. Eastern.
Activated
02/01/2014
Closed
08/31/2016
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Prednisone Abiraterone Acetate Enzalutamide

Publication Information Expand/Collapse

2023

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

M Morris;G Heller;D Hillman;O Conway;C Ryan;E Antonarakis;A Bryce;O Hahn;H Beltran;A Armstrong;L Schwartz;L Lewis;J Beumer;B Langevin;E McGary;P Mehan;A Goldkorn;B Roth;H Xiao;C Watt;M Taplin;S Halabi;E Small Journal of Clinical Oncology Jun 20;41(18):3352-3362

PMid: PMID36996380

2019

Results of Alliance A031201: A Phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for men with metastatic castration resistant prostate cancer (mCRPC)

MJ Morris;G Heller;A Bryce;A Armstrong;H Beltram;O Hahn;E McGary;P Mehan;A Goldkorn;B Roth;H Xiao;ME Taplin;CJ Ryan;S Halabi;E Small J Clin Oncol 37(suppl; abstr 5008); American Society of Clinical Oncology (5/31/2-6/4/19, Chicago IL), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase